Navigation Links
Experimental Blood Thinner Given Before Surgery Shows Benefit
Date:1/17/2012

TUESDAY, Jan. 17 (HealthDay News) -- An experimental anti-blood-clotting drug can serve as a replacement for other drugs such as Plavix in the days before heart surgery, a new study has found.

The intravenous drug cangrelor appears to have the potential to serve as a "bridge" medication for heart patients to take in the several days before procedures such as coronary artery bypass grafting, the study authors reported.

Anti-clotting drugs, also referred to as antiplatelet therapy or anticoagulants -- including clopidogrel, known by the brand name Plavix -- are often given to heart patients to prevent dangerous vessel-clogging blood clots. But they can cause too much bleeding during surgery, and guidelines suggest that doctors stop treatment with them in the five to seven days before an operation.

In the new study, Dr. Dominick Angiolillo of the University of Florida, Jacksonville, and colleagues gave cangrelor or a placebo to 210 patients who were about to undergo coronary artery bypass grafting. The patients had been treated with a thienopyridine (such as Plavix) but went off the drugs prior to surgery as recommended, then received cangrelor or placebo for at least 48 hours until one to six hours before surgery.

Angiolillo's team found that excessive bleeding related to surgery wasn't much more likely in the patients who took the drug (11.8 percent) compared to those who took the placebo (10.4 percent). Major bleeding problems before surgery were rare, while those who took cangrelor had more minor bleeding problems, according to the report published in the Jan. 18 issue of the Journal of the American Medical Association.

The investigators also found that the patients who took cangrelor reached levels of platelet inhibition that are linked to a lower risk of problems such as clots.

The findings make sense, said Dr. Gregg Stone, a heart specialist and professor of medicine at Columbia University in New York City. The study shows that cangrelor works rapidly and then dissipates when it isn't needed anymore so it doesn't boost the risk of bleeding during surgery, he said.

"This drug is investigational, so it is not yet an option for patients to ask about," Stone pointed out, "but if [the U.S. Food and Drug Administration] approved it, it would likely be widely used."

More information

For more about blood thinners, visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Gregg W. Stone, M.D., professor, medicine, Columbia University, New York City; Jan. 18, 2012, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Wolfson Foundation awards £20 million to UCL for experimental neurology center
2. Novel experimental agent is highly active in CLL patients, interim study shows
3. Experimental Drug for Irregular Heart Rhythm Raises Death Risk: Study
4. Experimental Drug Slims Obese Monkeys
5. Experimental Psoriasis Drug Bests Older Treatment
6. Experimental Vaccine Shows Promise for Lung Cancer: Study
7. Experimental vaccine protects monkeys from blinding trachoma
8. Experimental MS Drug Shows Promise
9. Researchers create new experimental vaccine against chikungunya virus
10. Experimental Drug Promising Against Tough-to-Treat Asthma
11. University Hospitals Case Medical Center to begin clinical trial on experimental anti-TB drug
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Blood Thinner Given Before Surgery Shows Benefit  
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc ... Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: ... , Results of the comparative usability study demonstrate that a dictation-based method (“NLP ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... With the ... created the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about ... Dentistry, the dental implant and prosthetic market in the U.S. is projected to reach ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... ... California Senate Bill (SB) 863, signed into law in 2012, may have ... according to CompScope™ Medical Benchmarks for California, 17th Edition , a study by ... payments per claim in California decreased 4 percent in 2013 and then 3 percent ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Pa. , Dec. 9, 2016 Department ... announced temporary regulations for medical marijuana dispensaries under Act ... Pennsylvania Bulletin , and are now available online ... is needed in the plan for operation; process for ... dispensary; as well as where the dispensary facilities can ...
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... in millions of US dollars, volume (in units) and ... Femtosecond Lasers and YAG Lasers. The report also ... of these market segements, and global corporate-level profiles of ...
(Date:12/8/2016)... Global Interventional Radiology Market: Scope and ... radiology market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
Breaking Medicine Technology: